EVerZom: Valuation, Funding & Investors
EVerZom is a French biotechnology company specializing in the development of exosome-based therapies for regenerative medicine. The company is advancing a proprietary bioproduction platform that leverages mesenchymal stem cell-derived exosomes, aiming to address high unmet medical needs across multiple therapeutic areas, including inflammatory diseases, hepatology, and dermatology. EVerZom's flagship product, EVerGel™, is set to enter clinical trials for Crohn's disease-related perianal fistulas, showcasing the potential of exosomes as a novel therapeutic modality.
Leadership & Board
- Current Number of Employees
- 26
- Current LinkedIn Followers
- 6,998
Latest Estimated Valuation
- Total Amount Raised
- $10M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $10M
- Latest Funding Round
- Investment
Employee Trend
EVerZom had 26 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
EVerZom had 6,998 followers as of October 26, 2026. The number of followers increased by 4 (0.06%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 14, 2025 | Investment | $10.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Capital Grand Est | Investment |
| European Innovation Council | Investment |
| Sorbonne Venture by Audacia | Investment |
| Aloe Private Equit | Investment |
| Paris Business Angels | Investment |
| Capital Cell platform | Investment |
| several family offices | Investment |
Similar Companies
A snapshot of private companies similar to EVerZom, helping you discover and navigate related company profiles.
Related News and Analysis
